tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

ANAB Stock Latest News

Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline
RatingsPositive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline
8d ago
ANAB
AnaptysBio price target raised to $51 from $40 at Wells Fargo
PremiumThe Fly
AnaptysBio price target raised to $51 from $40 at Wells Fargo
9d ago
ANAB
Positive Phase 2 Trial Results and Strong Safety Profile Boost Confidence in AnaptysBio’s Rosnilimab, Supporting Buy Rating and Increased Price Target
PremiumRatings
Positive Phase 2 Trial Results and Strong Safety Profile Boost Confidence in AnaptysBio’s Rosnilimab, Supporting Buy Rating and Increased Price Target
9d ago
ANAB
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
PremiumThe Fly
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
9d ago
ANAB
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
PremiumThe Fly
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
10d ago
ANAB
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results
PremiumCompany AnnouncementsAnaptysBio Announces Promising Phase 2b RENOIR Trial Results
10d ago
8K
ANAB
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
Premium
The Fly
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
10d ago
ANAB
AnaptysBio’s Strong Financial Prospects Driven by Jemperli’s Growth and Strategic Partnerships
Premium
Ratings
AnaptysBio’s Strong Financial Prospects Driven by Jemperli’s Growth and Strategic Partnerships
15d ago
ANAB
Hold Rating for AnaptysBio: Strategic Licensing Decision Amid Limited GPP Market and Competitive Challenges
PremiumRatings
Hold Rating for AnaptysBio: Strategic Licensing Decision Amid Limited GPP Market and Competitive Challenges
18d ago
ANAB
AnaptysBio initiated with an Outperform at Wolfe Research
PremiumThe Fly
AnaptysBio initiated with an Outperform at Wolfe Research
18d ago
ANAB
AnaptysBio initiated with an Outperform at Wolfe Research
PremiumThe Fly
AnaptysBio initiated with an Outperform at Wolfe Research
18d ago
ANAB
AnaptysBio Partners with Vanda for Imsidolimab Development
PremiumCompany Announcements
AnaptysBio Partners with Vanda for Imsidolimab Development
19d ago
8K
ANAB
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
PremiumThe FlyAnaptysBio, Vanda announce exclusive global license agreement for Vanda
19d ago
ANAB
VNDA
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Premium
The Fly
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
19d ago
ANAB
VNDA
AnaptysBio price target lowered to $36 from $66 at JPMorgan
Premium
The Fly
AnaptysBio price target lowered to $36 from $66 at JPMorgan
2M ago
ANAB
AnaptysBio price target lowered to $20 from $30 at Truist
PremiumThe Fly
AnaptysBio price target lowered to $20 from $30 at Truist
2M ago
ANAB
Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz
PremiumThe Fly
Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz
2M ago
GM
RH
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
ANAB
AUPH
Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz
PremiumThe Fly
Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz
2M ago
KO
CNC
AnaptysBio price target lowered to $36 from $90 at Guggenheim
PremiumThe FlyAnaptysBio price target lowered to $36 from $90 at Guggenheim
2M ago
ANAB
AnaptysBio price target lowered to $40 from $56 at Wells Fargo
Premium
The Fly
AnaptysBio price target lowered to $40 from $56 at Wells Fargo
2M ago
ANAB
AnaptysBio downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
AnaptysBio downgraded to Neutral from Buy at H.C. Wainwright
2M ago
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >